Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 07, 2023

SELL
$10.27 - $13.29 $31,837 - $41,199
-3,100 Reduced 32.98%
6,300 $0
Q3 2022

Oct 25, 2022

SELL
$9.93 - $17.44 $86,391 - $151,728
-8,700 Reduced 48.07%
9,400 $1,000
Q2 2022

Aug 04, 2022

BUY
$7.45 - $12.83 $28,310 - $48,754
3,800 Added 26.57%
18,100 $8,000
Q1 2022

Apr 14, 2022

SELL
$9.75 - $14.44 $130,650 - $193,496
-13,400 Reduced 48.38%
14,300 $13,000
Q4 2021

Jan 18, 2022

SELL
$13.17 - $20.94 $1.6 Million - $2.54 Million
-121,500 Reduced 81.43%
27,700 $16,000
Q3 2021

Oct 26, 2021

BUY
$9.16 - $19.83 $1.22 Million - $2.64 Million
133,100 Added 826.71%
149,200 $93,000
Q2 2021

Jul 19, 2021

BUY
$7.25 - $10.99 $2,175 - $3,297
300 Added 1.9%
16,100 $22,000
Q1 2021

Apr 26, 2021

SELL
$4.57 - $11.18 $117,449 - $287,326
-25,700 Reduced 61.93%
15,800 $25,000
Q4 2020

Jan 21, 2021

SELL
$3.73 - $5.6 $71,989 - $108,080
-19,300 Reduced 31.74%
41,500 $3,000
Q3 2020

Oct 27, 2020

SELL
$4.32 - $11.7 $461,376 - $1.25 Million
-106,800 Reduced 63.72%
60,800 $22,000
Q2 2020

Jul 22, 2020

BUY
$2.94 - $9.1 $492,744 - $1.53 Million
167,600 New
167,600 $343,000
Q1 2019

May 10, 2019

SELL
$7.08 - $12.09 $15,576 - $26,598
-2,200 Closed
0 $0
Q3 2018

Nov 07, 2018

SELL
$11.85 - $16.0 $68,730 - $92,800
-5,800 Reduced 72.5%
2,200 $1,000
Q2 2018

Aug 10, 2018

BUY
$15.15 - $20.75 $59,085 - $80,925
3,900 Added 95.12%
8,000 $2,000
Q1 2018

May 11, 2018

SELL
$14.65 - $19.9 $175,800 - $238,799
-12,000 Reduced 74.53%
4,100 $9,000
Q4 2017

Jan 17, 2018

SELL
$17.3 - $24.08 $273,340 - $380,464
-15,800 Reduced 49.53%
16,100 $48,000
Q3 2017

Oct 17, 2017

BUY
$15.2 - $21.5 $484,880 - $685,850
31,900
31,900 $247,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.64B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.